WFS1 Gene-associated Diabetes Phenotypes and Identification of a Founder Mutation in Southern India.
- Christian Medical College Vellore, India.
- Moulana Hospital, Mallapuram, India.
- BP Koirala Institute of Health Sciences, Nepal.
- The National Hospital of Srilanka, Colombo, Srilanka.
- Max Super Speciality Hospital, New Delhi, India.
- Institute of Post-Graduate Medical Education and Research, Kolkotta, India.
- Madras Diabetes Research Foundation, Chennai, India.
- Sagar Hospitals, Bengaluru, India.
The Journal of clinical endocrinology and metabolism Vol. 107 · Issue 5 · pp. 1328-1336
PMID 35018440 DOI 10.1210/clinem/dgac002
Cite This Article
Aaron Chapla, Jabasteen Johnson, Sophy Korula, Nisha Mohan, Anish Ahmed, Deny Varghese, Parthiban Rangasamy, Lavanya Ravichandran, Felix Jebasingh, Krishna Kumar Agrawal, Noel Somasundaram, Asha Hesarghatta Shyamasunder, Sarah Mathai, Anna Simon, Sujeet Jha, Subhankar Chowdry, Radha Venkatesan, Palany Raghupathy, Nihal Thomas. WFS1 Gene-associated Diabetes Phenotypes and Identification of a Founder Mutation in Southern India. The Journal of clinical endocrinology and metabolism. 2022;107(5):1328-1336. doi:10.1210/clinem/dgac002
Abstract
CONTEXT: Wolfram syndrome (WFS) is a rare autosomal recessive disorder characterized by juvenile-onset diabetes, diabetes insipidus, optic atrophy, deafness, and progressive neurodegeneration. However, due to the progressive nature of the disease and a lack of complete clinical manifestations, a confirmed diagnosis of WFS at the time of onset of diabetes is a challenge.
OBJECTIVE: With WFS1 rare heterozygous variants reported in diabetes, there is a need for comprehensive genetic screening strategies for the early diagnosis of WFS and delineating the phenotypic spectrum associated with the WFS1 gene variants in young-onset diabetes.
METHODS: This case series of 11 patients who were positive for WFS1 variants were identified with next-generation sequencing (NGS)-based screening of 17 genemonogenic diabetes panel. These results were further confirmed with Sanger sequencing.
RESULTS: 9 out of 11 patients were homozygous for pathogenic/likely pathogenic variants in the WFS1 gene. Interestingly, 3 of these probands were positive for the novel WFS1 (NM_006005.3): c.1107_1108insA (p.Ala370Serfs*173) variant, and haplotype analysis suggested a founder effect in 3 families from Southern India. Additionally, we identified 2 patients with young-onset diabetes who were heterozygous for a likely pathogenic variant or a variant of uncertain significance in the WFS1 gene.
CONCLUSION: These results project the need for NGS-based parallel multigene testing as a tool for early diagnosis of WFS and identify heterozygous WFS1 variants implicated in young-onset diabetes.
Keywords
- WFS1
- DIDMOAD
- Wolfram syndrome
- founder mutation
- next-generation sequencing




